On September 19th, the House of Representatives passed the Recalcitrant Cancer Research Act, which establishes a new targeted scientific research framework within NCI to address those cancers whose 5-year survival rates are less than 50%. Priority status was given to pancreatic and lung cancer.
The United States Senate prepared to consider the legislation this past weekend but unfortunately did not pass it before recessing for the Presidential elections. Congress is now out of session but will return November 13TH to consider unfinished business of the 112th Congress. We will continue to monitor and advocate for the passage of this important legislation during this time and will keep you apprised of the